MeiraGTx Holdings Plc (MGTX)

In the past six months, MeiraGTx announced a strategic collaboration with Eli Lilly and Company to develop and commercialize genetic medicines in ophthalmology. The company reported its third-quarter 2025 financial and operational results, posting a loss of $0.62 per share and missing revenue estimates. The company released its second-quarter 2025 financial and operational results. MeiraGTx announced presentations at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress and the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting. The stock reached a 52-week high of $9.73 on November 10, 2025, and as of January 2, 2026, the share price was $7.81. Analysts have provided a consensus rating of "Moderate Buy" for MGTX, with an average rating score of 2.83.

As a clinical-stage gene therapy company, MeiraGTx Holdings Plc's products are primarily in development and not yet widely commercialized, so traditional demand seasonality does not apply. Revenue is currently generated from collaborations and research activities rather than product sales.

MeiraGTx Holdings Plc is a clinical-stage gene therapy company focused on developing genetic medicines for serious diseases within the Healthcare sector, specifically in the Biotechnology industry. The company is vertically integrated, encompassing both product development and in-house manufacturing. Its pipeline products target ocular diseases, salivary gland disorders, and central nervous system disorders, including treatments for achromatopsia, X-linked retinitis pigmentosa, xerostomia, Parkinson's disease, and other inherited retinal and CNS disorders. The company also provides a riboswitch platform for the delivery of metabolic peptides and cell therapies.

MeiraGTx Holdings Plc operates in the United States, the United Kingdom, and the European Union, with its corporate office located in New York, NY. The company's operations extend across North America and Europe.

MeiraGTx has maintained a positive brand reputation over the past year, driven by advancements in its clinical programs and strategic collaborations. Positive clinical trial results for its investigational gene therapy for AIPL1-associated severe retinal dystrophy were highlighted in news outlets. The company received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for AAV-GAD for Parkinson's disease and Rare Pediatric Disease Designation from the FDA for its AAV8-RK-RetGC program for Leber congenital amaurosis due to GUCY2D mutations (LCA1). A collaboration with Eli Lilly and Company for ophthalmology genetic medicines and a strategic collaboration with Hologen AI have positively impacted its standing. The company has a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.83.

MeiraGTx Holdings Plc has 227 institutional owners and shareholders, holding a total of 67,020,030 shares, including Perceptive Advisors Llc, Sanofi, and Johnson & Johnson Innovation - JJDC, Inc. Individual insiders have sold more of the company's stock than they have bought in the past three months, with $212,880.00 in sales and $0.00 in purchases. Institutions hold 67.48% of the stock.